Patents Assigned to Medimmune
  • Antibodies that specifically bind alpha toxin and methods of use
    Patent number: 9527905
    Abstract: Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Lei Hua, Partha Chowdhury, Reena Varkey, Melissa Damschroder, Li Peng, Vaheh Oganesyan, Jamese Johnson Hilliard
  • Modified polypeptides for bispecific antibody scaffolds
    Patent number: 9527927
    Abstract: The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Partha S. Chowdhury, Vaheh Oganesyan, Yariv Mazor, Nazzareno Dimasi
  • THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
    Publication number: 20160347848
    Abstract: Provided herein are methods of treating a solid tumor comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof, tremelimumab or an antigen-binding fragment thereof, and MEDI6383.
    Type: Application
    Filed: May 9, 2016
    Publication date: December 1, 2016
    Applicant: MedImmune Limited
    Inventors: Scott A. HAMMOND, Kathleen Ann MULGREW, Michael OBERST, Edward BRADLEY, Ross A. STEWART
  • TUBULYSIN DERIVATIVES
    Publication number: 20160339114
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Application
    Filed: August 8, 2016
    Publication date: November 24, 2016
    Applicant: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Antibodies against and methods for producing vaccines for respiratory syncytial virus
    Patent number: 9499590
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: November 22, 2016
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, JoAnn Suzich
  • Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
    Patent number: 9493570
    Abstract: The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: November 15, 2016
    Assignee: MedImmune, LLC
    Inventors: Brandon Higgs, Yihong Yao, Bing Wang, Lorin Roskos, Linda Chang
  • Targeted binding agents against B7-H1
    Patent number: 9493565
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 15, 2016
    Assignee: MedImmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
  • PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
    Publication number: 20160310611
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: October 27, 2016
    Applicants: Genentech Inc., Medimmune Limited
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Specific Binding Members for NGF
    Publication number: 20160297878
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 13, 2016
    Applicant: MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20160251412
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 1, 2016
    Applicant: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • ANTIBODY PURIFICATION
    Publication number: 20160251441
    Abstract: Described herein is a method for separating antibody fragment impurities from target antibodies or desired fragments thereof.
    Type: Application
    Filed: October 23, 2014
    Publication date: September 1, 2016
    Applicant: MedImmune, LLC
    Inventors: Ellen T. O'CONNOR, Mutsa Y. KAMBARAMI, Matthew T. ASPELUND, Frank L. BARTNIK, Mark BERGE, Thoa BUI, Methal ALBARGHOUTHI, Jihong WANG, Jun KIM
  • Tubulysin derivatives
    Patent number: 9427479
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 30, 2016
    Assignee: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF
    Publication number: 20160237162
    Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: September 23, 2014
    Publication date: August 18, 2016
    Applicant: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
  • Antibodies Against PD-1 and Uses Thereof
    Publication number: 20160222113
    Abstract: The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders.
    Type: Application
    Filed: September 9, 2014
    Publication date: August 4, 2016
    Applicant: MedImmune Limited
    Inventors: Andrew Buchanan, Ross Stewart, Mathieu Chodorge
  • Anti-pseudomonas Psl binding molecules and uses thereof
    Patent number: 9403901
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 2, 2016
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
    Publication number: 20160185837
    Abstract: This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes.
    Type: Application
    Filed: August 15, 2014
    Publication date: June 30, 2016
    Applicant: Medimmune Limited
    Inventors: Maria Bednarek, Andie Collinson, David Hornigold, Siobhan O'Brien, Monika Papworth, Peter Ravn, Isabelle Sermadiras
  • STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS
    Publication number: 20160159886
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 9, 2016
    Applicant: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF
    Publication number: 20160129108
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 12, 2016
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon
  • RSV-specific binding molecules and means for producing them
    Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Specific binding members for NGF
    Patent number: 9315571
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: April 19, 2016
    Assignees: Elan Pharma International Limited, MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson